ECOG Performance status
Grade 0: Fully active, able to carry on all pre-disease performance without restriction 2 (10)
Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
(70)
Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
(20)
Qualitative interviews to provide in-depth understanding of the impact of non-small cell lung cancer (NSCLC) and its treatment on the lives of patients and their families/caregivers Introduction >> Lung cancer is one of the leading causes of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and has a 5 year survival rate of approximately 8% 1 . >> NSCLC is associated with the symptoms pain, breathlessness, hoarseness and coughing, which can be present prior to diagnosis and continue throughout the course of the disease, adversely affecting patients' functional status and quality of life. 3-22 >> Treatment is associated with severe side effects 5, 8, 10 and can be logistically burdensome in terms of the time required to attend appointments. 10, 23 In addition, there is considerable burden placed on the informal caregivers and families who provide physical, emotional, financial and logistical support to patients with NSCLC. 9, 15, 16, 18, 19, [23] [24] [25] [26] [27] >> In addition to overall and progression free survival; the improvement, maintenance or delayed deterioration of health related quality of life (HRQoL) are desirable outcomes of any lung cancer treatment. When assessing HRQoL in clinical trials it is critical that the instruments being used adequately capture the concepts which are most important to patients and that have the greatest impact on their quality of life, in addition to being valid, reliable and sensitive to changes over time. 28, 29 Objectives >> The aim of this study was to further understand the patient experience of advanced NSCLC and its treatment including the burden of disease on patients and their caregivers or families. >> More specifically, the aim was to better understand which aspects of disease and its treatment and care have the greatest detrimental impact on quality of life in order to understand what patients would value most from new treatments.
Methods
>> Face-to-face, open-ended and semi-structured qualitative interviews were conducted with 20 patients with advanced stage lll/IV NSCLC. >> Patients were identified via clinician referrals from two specialist oncology treatment and research centres in the UK. Eligible participants had completed at least one line of therapy. >> Adequacy of sample size was justified based on the principal of conceptual saturation which is considered to be achieved at the point when no new concepts emerge with the repeated collection of additional information. A sample size of 12 or more is usually considered adequate for conceptual saturation. 30,31 >> All interviews were conducted by trained interviewers at either the participants' homes or the hospital site. Initial questions were designed to be unbiased and elicit spontaneous responses (e.g. "Can you tell me about your experience with lung cancer?") Following this, answers were discussed in more detail using probes when appropriate (e.g. "tell me more about that"; "how did that impact you?"). Creative tasks were also used to elicit content, for example an impact rating ladder ( Figure 1 ). 
Psychological Impact
Dealing with the diagnosis of NSCLC
(45)
"It is really difficult…everybody is going to die at some point, but I know that it's probably going to happen within the next couple of years -unless something marvelous happens, so -hard to live with -yeah and it doesn't go away…you can't switch it off" female, aged 37 20 (100) "we've been so busy kind of going through all the treatments, doing all of that, and trying to fit everything else in around it" female, aged 37
Travelling to treatment and appointments 5 (25) "It's a train journey for us every time we go up the hospital. You know, which is quite horrendous at times." male, aged 72
Receiving treatment 11 (55) "The worst thing is when you sat there for three-three and a half hours, the drips you have now, as well. Because you can only read the paper from back to front once, yeah?" male, aged 68
Scheduling of appointments:
time of day of appointments and the unpredictability of the schedule 9 (45) "It's quite quick. It's a nuisance because it's in the middle of the day. And they can't do any other time but the middle of the day, which messes up your entire day." female, aged 63
Recovering from treatment: the days to weeks after treatment
(65)
"The chemo knocks you back a bit, but, uh, you know, you're really tired, you know. "Q: And how long do you stay tired for after the chemo?" "Uh, about a couple of weeks or so. You're just getting better when you're going for another whack, you know." male, aged 85
Conclusions
>> This study demonstrates that limitations of the ability of patients to do the things they wish to do and time taken receiving and recovering from treatment are bothersome impacts to patients with NSCLC. >> However, the performance status of most participants included in this study was relatively high (70% had ECOG status of Grade 1),and so findings may not be generalisable to patients with a poorer health status. >> Over half of those interviewed valued quality of life over quantity of life. This highlights the importance of including instruments in clinical trials that capture all elements of the disease and treatment/care which impact patients' quality of life and the importance of assessing quality of life more robustly and comprehensively in clinical trials. >> These findings suggest that the most detrimental impacts on patients' lives may lie outside of what is typically assessed in HRQoL in lung cancer instruments.The insight into the patient experience and the perceived experience of their caregivers and family, can be used to inform the optimal design and inclusion of outcome assessments in clinical trials. >> The concepts identified provide evidence for what is important to patients and the entire patient risk/benefit of new treatments and care which could be taken into consideration by healthcare providers, regulators and funding decision-makers. >> In addition, healthcare providers and decision-makers should aim to ensure that all factors valued by patients such as communication and continuity of care and consideration of the time required of patients to engage in and recover from treatment are taken into account in the provision of treatment and care plans.
>> Interviews were transcribed verbatim and Atlas.Ti software was used to conduct thematic analysis. The thematic analysis process involved creating and assigning data-driven codes to sections of text. These codes were then grouped according to their underlying theme/concept. This approach enables concepts to be derived from the words of the participants, rather than from the application of a priori theory or understanding. >> This study was approved by the National Research Ethics Service (NRES) in the UK (NRES Committee Yorkshire & The Humber -South Yorkshire) and R&D approval was obtained from the NHS trusts from which the study recruited participants. 
Symptom

Findings
Demographic and Clinical Characteristics
Symptoms and side effects >> Participants reported experiencing a number of symptoms and side effects, however it was not always possible for them, or the researchers, to attribute whether a symptom they experienced was due to the disease or to the treatment they were receiving. >> Concepts were organised into three groups: symptoms (where concepts were attributed to the disease), symptoms/side effects (where attribution was unclear), and side effects (concepts that could clearly be attributed to treatment). These concepts are represented in Figure 2 .
Quality of life vs. extending life
>> Sixteen participants were asked if they would prioritise quality of life or extending life.
>> Just over half of participants (n=11, 55%) reported that given the option, they would prefer treatment to improve or maintain quality of life over extending life.
>> Five participants (25%) said they would prioritise or would consider treatment that could extend life.
"I would just say a better quality of life it's like the winning the lottery. I -I don't want the lottery. 
